JP2021502809A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502809A5 JP2021502809A5 JP2020524841A JP2020524841A JP2021502809A5 JP 2021502809 A5 JP2021502809 A5 JP 2021502809A5 JP 2020524841 A JP2020524841 A JP 2020524841A JP 2020524841 A JP2020524841 A JP 2020524841A JP 2021502809 A5 JP2021502809 A5 JP 2021502809A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- mmdsc
- region
- methylation
- cpg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017126248.2 | 2017-11-09 | ||
| DE102017126248.2A DE102017126248B4 (de) | 2017-11-09 | 2017-11-09 | ERGIC1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesonderemonozytischem myeloid-abgeleiteten Suppressor-Zellen (mMDSCs) |
| PCT/EP2018/080235 WO2019091942A1 (en) | 2017-11-09 | 2018-11-06 | ERGIC1 AS EPIGENETIC MARKER FOR THE IDENTIFICATION OF IMMUNE CELLS, IN PARTICULAR MONOCYTIC MYELOID-DERIVED SUPPRESSOR CELLS (mMDSCs) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502809A JP2021502809A (ja) | 2021-02-04 |
| JP2021502809A5 true JP2021502809A5 (https=) | 2021-08-19 |
Family
ID=64184067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524841A Pending JP2021502809A (ja) | 2017-11-09 | 2018-11-06 | 免疫細胞、特に単球性骨髄由来抑制細胞（ｍＭＤＳＣ）の同定のためのエピジェネティックマーカーとしてのＥＲＧＩＣ１ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11976327B2 (https=) |
| EP (1) | EP3669005B1 (https=) |
| JP (1) | JP2021502809A (https=) |
| CN (1) | CN111315896A (https=) |
| AU (1) | AU2018364335A1 (https=) |
| DE (1) | DE102017126248B4 (https=) |
| WO (1) | WO2019091942A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2869295A1 (en) | 2011-05-25 | 2012-11-29 | Brown University | Methods using dna methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies |
| JP6590790B2 (ja) * | 2013-04-19 | 2019-10-16 | エピオンティス ゲーエムベーハー | 生体サンプルにおける定量的細胞組成を特定する方法 |
| US10190169B2 (en) | 2013-06-20 | 2019-01-29 | Immunexpress Pty Ltd | Biomarker identification |
| EP3132055A2 (en) | 2014-04-14 | 2017-02-22 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | A method and kit for determining the tissue or cell origin of dna |
-
2017
- 2017-11-09 DE DE102017126248.2A patent/DE102017126248B4/de active Active
-
2018
- 2018-11-06 US US16/762,534 patent/US11976327B2/en active Active
- 2018-11-06 WO PCT/EP2018/080235 patent/WO2019091942A1/en not_active Ceased
- 2018-11-06 CN CN201880071954.8A patent/CN111315896A/zh not_active Withdrawn
- 2018-11-06 JP JP2020524841A patent/JP2021502809A/ja active Pending
- 2018-11-06 AU AU2018364335A patent/AU2018364335A1/en not_active Abandoned
- 2018-11-06 EP EP18799716.8A patent/EP3669005B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arock et al. | KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis | |
| Jara-Acevedo et al. | Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications | |
| JP6189600B2 (ja) | Ｔ細胞受容体ｖ／ｄ／ｊ遺伝子内の反復配列によるクローン細胞の同定 | |
| EP3327141B1 (en) | Method for identifying the quantitative cellular composition in a biological sample | |
| Muthaiah et al. | Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates | |
| JP2018529345A5 (https=) | ||
| Wysocka et al. | CD164 and FCRL3 are highly expressed on CD4+ CD26− T cells in Sezary syndrome patients | |
| JP2012511917A5 (https=) | ||
| JP2018529346A5 (https=) | ||
| Weber | Biomarkers for checkpoint inhibition | |
| JP2018534910A5 (https=) | ||
| JP4088694B2 (ja) | 造血器腫瘍の検査方法およびキット | |
| JP6543573B2 (ja) | ＣＤ８＋Ｔリンパ球、特にＣＤ８α及びβＴリンパ球の亜集団の同定用のエピジェネティック法 | |
| CN108026577B (zh) | Mvd作为用于鉴定免疫细胞特别是cd56+nk细胞的表观遗传标志物 | |
| KR20160143113A (ko) | 한국인 가족성 고콜레스테롤혈증에서 다유전자 기인성 | |
| DK2734638T3 (en) | Epigenetic marker to identify natural killer cells | |
| JP2021502809A5 (https=) | ||
| JP5009289B2 (ja) | Ｍａｌｔリンパ腫の検査方法及びキット | |
| JP2021502806A5 (https=) | ||
| WO2015052190A1 (en) | Predicting increased risk for cancer | |
| JPWO2020179646A1 (ja) | 成人ｔ細胞白血病／リンパ腫の検出方法 | |
| CN121109595B (zh) | 一种肺癌检测或诊断的标志物组合物、产品及其应用 | |
| CA2901150A1 (en) | Method and apparatus of aiding detection of surface abnormality in the oesophagus | |
| JP6763611B2 (ja) | アスベスト曝露歴または中皮腫の検査方法 | |
| JP2021502809A (ja) | 免疫細胞、特に単球性骨髄由来抑制細胞（ｍＭＤＳＣ）の同定のためのエピジェネティックマーカーとしてのＥＲＧＩＣ１ |